SCHEMBL9192590

SCHEMBL9192590

Nn1cc(F)c(=O)[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
GRIA1 P42261 1/20 0.45
GRIA2 P42262 1/20 0.45
GRIA3 P42263 1/20 0.45
GRIA4 P48058 1/20 0.45
GRIK5 Q16478 1/20 0.45
LMNA P02545 8/20 0.41
MAPT P10636 3/20 0.41
ESR1 P03372 1/20 0.41
CRBN Q96SW2 1/20 0.40
SMN1; SMN2 Q16637 5/20 0.39
TSHR P16473 2/20 0.39
PMP22 Q01453 2/20 0.39
HBB P68871 2/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.37
CYP19A1 P11511 1/20 0.37
THPO P40225 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28047504 0.74 LMNA (0.44) KDM4ECYP1A2GRIA1GRIA2GRIA3
SCHEMBL646139 0.74 TDP1 (0.59) TDP1LMNACRBNALDH1A1HPGD
SCHEMBL400005 0.73 TDP1 (1.00) TDP1CYP1A2GRIA1GRIA2GRIA4
SCHEMBL22463402 0.73 LMNA (0.41) KDM4ECYP1A2GRIA1GRIA2GRIA3
SCHEMBL11327834 0.73 LMNA (0.41) KDM4ECYP1A2GRIA1GRIA2GRIA3
SCHEMBL9190653 0.73 TDP1 (0.57) TDP1CYP1A2GRIA1GRIA2GRIA4
SCHEMBL9192075 0.73 TDP1 (0.57) TDP1KDM4ECYP1A2GRIA1GRIA2
SCHEMBL4379234 0.73 LMNA (0.46) KDM4ECYP1A2GRIA1GRIA2GRIA3
SCHEMBL18659115 0.73 LMNA (0.41) KDM4ECYP1A2GRIA1GRIA2GRIA3
SCHEMBL13067325 0.73 LMNA (0.42) KDM4ECYP1A2GRIA1GRIA2GRIA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-56128769-A None JP disclosed
CN-116457339-A Tricyclic compounds degrading novel substrates for medical treatment C4医药公司 2023-07-18 CN disclosed
WO-2017053391-A1 MODIFIED CYTOTOXINS AND THEIR THERAPEUTIC USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-03-30 WO disclosed
CN-102439040-A anti-TNF-alpha antibodies and uses thereof FACET BIOTECH CORP 2012-05-02 CN disclosed
EP-2280281-A1 5-fluoro-uracil immunoassay Saladax Biomedical Inc. (US) 2011-02-02 EP disclosed
EP-0425669-B1 1-AMINO-5-HALOGENOURACILS, PROCESS FOR THEIR PREPARATION, AND CENTRAL NERVOUS SYSTEM DEPRESSANTS CONTAINING SAME AS ACTIVE INGREDIENT YAMASA SHOYU KK (JP) 1995-01-25 EP disclosed
US-5334593-A Anxiolytic drugs YAMASA SHOYU KABUSHIKI KAISHA (JP) 1994-08-02 US disclosed
US-5252576-A 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient YAMASA SHOYU KABUSHIKI KAISHA (JP) 1993-10-12 US disclosed
EP-0509098-A1 ATARACTIC Yamasa Shoyu Kabushiki Kaisha (JP) 1992-10-21 EP disclosed
EP-0425669-A1 1-AMINO-5-HALOGENOURACILS, PROCESS FOR THEIR PREPARATION, AND CENTRAL NERVOUS SYSTEM DEPRESSANTS CONTAINING SAME AS ACTIVE INGREDIENT Yamasa Shoyu Kabushiki Kaisha also trading as Yamasa Corporation (JP) 1991-05-08 EP disclosed
JP-S56128769-A AMINO-5-FLUOROURACIL DERIVATIVE AND ITS PREPARATION TAIHO YAKUHIN KOGYO KK 1981-10-08 JP disclosed